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Motor impairments of the upper and lower extremities are common symptoms of multiple
sclerosis (MS). While some peripheral effects like muscle weakness and loss of balance
have been shown to influence these symptoms, central nervous system activity has not
been fully elucidated. The purpose of this study was to determine if alterations in glucose
uptake were associated with motor impairments in patients with multiple sclerosis. Eight
patients with multiple sclerosis (four men) and eight sex matched healthy controls per-
formed 15 min of treadmill walking at a self-selected pace, during which ≈322 MBq of the
positron emission tomography (PET) glucose analog [18F]-fluorodeoxyglucose (FDG) was
injected. Immediately after the cessation of walking, participants underwent PET imaging.
Patients with MS had lower FDG uptake in≈40% of the brain compared to the healthy con-
trols (pFWE-corr<0.001, qFDR-corr<0.001, ke=93851) and walked at a slower speed [MS,
1.1 (0.2), controls 1.4 (0.1), m/s, P =0.014]. Within the area of lower FDG uptake 15 regions
were identified. Of these 15 regions, 13 were found to have strong to moderate correlations
to walking speed within the healthy controls (r>−0.75, P <0.032). Within patients with
MS only 3 of the 15 regions showed significant correlations: insula (r =−0.74, P =0.036),
hippocampus (r =−0.72, P =0.045), and calcarine sulcus (r =−0.77, P =0.026). This data
suggest that walking impairments in patients with MS may be due to network wide alter-
ations in glucose metabolism. Understanding how brain activity and metabolism are altered
in patients with MS may allow for better measures of disability and disease status within
this clinical population.
Keywords: positron emission tomography, glucose uptake, multiple sclerosis, walking, brain activity, movement
disorder
INTRODUCTION
Motor impairments of the upper and lower extremities are some
of the most common symptoms in patients with MS (Fox et al.,
2006). Previous investigations have shown muscle weakness, spas-
ticity, and loss of coordination/balance as contributors to these
motor decrements (Rizzo et al., 2004; Fritz et al., 2014; Wagner
et al., 2014). One area that has been less studied is how alterations
in motor patterns generated within the central nervous system
(CNS) may play a role. The most common methods for elucidating
information about CNS activity during motor task performance
are functional magnetic resonance imaging (fMRI) and electroen-
cephalography (EEG). A major limitation of fMRI is that brain
activity can only be measured while an individual is positioned
within the MR camera (Gramann et al., 2014). While EEG is able
to measure activity during walking, it can be hampered by inter-
ference and is unable to measure subcortical areas (Filippi et al.,
2002).
An alternative to fMRI and EEG is positron emission tomo-
graphy (PET). Using the PET glucose analog [18F]-fluorodeoxy-
glucose (FDG), the brains utilization/uptake of FDG can be quan-
tified. Glucose is one of the main substrates the brain uses to
generate ATP. By measuring FDG uptake into the CNS estimates
of brain activity can be made (Ginsberg et al., 1988; Niccolini
et al., 2015). FDG PET also allows for the quantification of all
brain regions during any type of free living activity, such as walk-
ing, running, or driving a car (Tashiro et al., 2001; Jeong et al.,
2006; La Fougere et al., 2010).
Utilizing FDG PET at rest, Roelcke et al. (1997) and Bakshi
et al. (1998) found reduced glucose metabolism within the brain of
patients with MS compared to healthy controls. Bakshi et al. (1998)
also suggested that cerebral dysfunction and neuronal system dis-
connection, or uncoupling, may play an important role in the
symptoms of MS. The purpose of this study was to determine the
associations between brain activity, as measured by FDG uptake,
and walking ability in patients with MS and healthy controls. We
hypothesized that patients with MS would have lower FDG uptake
during walking compared to controls, and that associations with
brain regions responsible for motor task performance/control are
altered in patients with MS.
MATERIALS AND METHODS
Basic descriptions of the methods utilized in this investigation
are provided here. A more detailed explanation can be found in
Rudroff et al. (2014). All testing was performed between the hours
of 0700 and 1100 to reduce the influence of fatigue on patients
with MS.
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PARTICIPANT RECRUITMENT
Eight patients with MS and eight controls participated in this
study. Basic inclusion criteria for patients with MS included pos-
itive MS diagnosis, ability to walk 15 min without assistance, and
no change in disease status/had a relapse within the previous
3 months. Controls were sex matched and without known cardio-
vascular, neurological, or musculoskeletal disease. All procedures
were approved by the Colorado Multi Institutional Review Board
and all experiments conformed to the Declaration of Helsinki.
Upon arrival to the Colorado Translational Research Imaging Cen-
ter all participants signed informed consent. Measurements for
height, weight, and age were obtained for all participants. Patients
with MS were assessed for disability utilizing the patient deter-
mined disease steps (PDDS) and the modified Ashworth scale
for grading spasticity (MASS). Figure 1 is a representation of the
experimental timeline. Participant characteristics are displayed in
Table 1.
WALKING TEST
Participants were asked to walk down a 60 m hallway 3–5 times.
The time it took them to walk the middle 20 m was timed with
a handheld stopwatch. The two closest times were averaged and
this speed was set as the initial speed of the treadmill. After their
comfortable walking speed was calculated and set on the treadmill,
participants began 15 min of treadmill walking. Any adjustments
to this speed were made within the first 2 min. Two minutes after
the start of treadmill walking ≈321.9 MBq of FDG was injected
into an antecubital vein via a previously inserted catheter. During
treadmill walking, participants were asked their rating of perceived
FIGURE 1 | Representative image of the experimental timeline.
Table 1 | Subject characteristics and clinical measures.
N MS CON P -value
8 (4 women) 8 (4 women)
Age (years) 44.9 (8.6) 37.9 (8.4) 0.122
Height (cm) 175 (8) 176 (7) 0.949
Weight (kg) 78.2 (3.3) 78.2 (6.3) 0.982
Disease duration (years) 8.9 (6.2)
PDDS 2 (0-4)
MASS 1 (0-1.5)
Walking speed (m/s)* 1.1 (0.2) 1.4 (0.1) 0.014
RPE 1.7 (1.4) 1.5 (1.1) 0.681
Age, height, weight, disease duration, walking speed, and RPE are reported as
mean (SD).
PDDS, patients determined disease steps; and MASS, modified Ashworth scale
for grading spasticity, are reported as median (range).
*P<0.050.
exertion (RPE), measured on the 10 point Borg scale, every minute.
At the conclusion of treadmill walking, participants were escorted
to the PET/computed tomography (CT) camera, and within 2 min
underwent the start of PET/CT imaging.
PET/CT IMAGING
Positron emission tomography/CT imaging was performed on a
Phillips Hybrid Gemini TF 64 camera (Philips Healthcare, Cleve-
land, OH, USA). PET images were acquired in list-mode and in
3-D mode, utilizing time-of-flight technology in order to improve
the image contrast vs. noise. A standard Colorado Translational
Research Imaging Center testing protocol was utilized. PET/CT
images were acquired consecutively with the participants’ body
secured to maintain co-registration of the images.
IMAGE ANALYSIS
Positron emission tomography images were cropped using Analyze
11.0 (Mayo Clinic, Rochester, MN, USA) to allow for analysis of the
brain via the Statistical Parametric Mapping 8 (SPM8)1 toolbox
for Matlab 2011a (The MathWorks, Inc., Natick, MA, USA). FDG
PET images were then transformed into SUV parametric images
using voxel by voxel calculation via the formula: SUV=Activity
(kBq/cc)/((Injected Activity (MBq)/Body Weight (kg)). After SUV
calculation, images were spatially normalized to a tracer specific
template into Montreal Neurological Institute (MNI) space, as
described in Tuulari et al. (2013). Images were smoothed at 10-
mm Full Width at Half Maximum. Smoothed spatially normalized
SUV images were then analyzed with SPM8.
A two-sample t -test batch process was performed within SPM8
to identify clusters of differing FDG uptake between the two
groups (group 1 MS, group 2 CON), utilizing walking speed as a
covariate, and a relative threshold masking set at 0.8. T -contrasts
of “−1 1” and “1 −1” were tested with a P-value set to 0.01 and
an extent threshold (ke)= to 0 (voxels). Whole brain and cur-
rent cluster values were identified at the cluster level. The SUV
for regions within the significant cluster level were determined
using the automatic anatomic labeling (AAL) template extracted
with the marsbar2 SPM toolbox. Visual inspection of the over-
lap between ROIs and SPM threshold output overlaid on the AAL
template was performed using MRIcron (Rorden and Brett, 2000).
STATISTICAL ANALYSIS
Whole brain statistical analysis was performed within SPM8 tool-
box and ROI-based Pearson’s correlations, brain region to walk-
ing speed, were performed with SPSS 22 (IBM Corp, Armonk,
NY, USA). Participant characteristics were compared utilizing
unpaired t -tests. For analysis performed in SPSS, a significant α
was set at <0.050.
RESULTS
SUBJECT CHARACTERISTICS
There were no differences between the MS and CON group for
age, height, or weight (P > 0.122). Patients with MS were clas-
sified as having mild disability determined from scores of the
1www.fil.ion.ucl.ac.uk/spm/
2http://marsbar.sourceforge.net
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MASS and PDDS. Patients with MS walked at a slower self-selected
speed than controls (P = 0.014), but without a difference in RPE
(P = 0.681). All participant characteristics are provided in Table 1.
These characteristics have been previously reported (Rudroff et al.,
2014).
SPM ANALYSIS
[18F]-fluorodeoxyglucose uptake in patients with MS was
lower compared to controls, represented by one large cluster
(pFWE-corr < 0.001, qFDR-corr < 0.001, ke= 93851) (Figure 2). This
cluster represented ~40% of total brain volume (227456 voxels).
No cluster or peak-level regions were found to have higher FDG
uptake in patients with MS. Figure 3 is the cluster-level SPM out-
put for the identified cluster, displaying peak-level information.
Table 2 displays SPM output with associated AAL labels defined
using MRIcron.
ROI ANDWALKING SPEED CORRELATIONS
Strong to moderate Pearson correlations were found in 13 out of
15 regions identified from SPM analysis to walking speed within
the control group (r>−0.75, P < 0.032). Within the MS group
only three regions, the insula (r =−0.74, P = 0.036), hippocam-
pus (r =−0.72, P = 0.045), and calcarine sulcus (r =−0.77,
P = 0.026) were found to have statistically significant correlations.
In both groups neither the thalamus nor caudate had a significant
correlation, although within the control group it was borderline
(0.051≤ P< 0.063). In general all other areas, while not reaching
statistical significance, had a lower Pearson r-value compared to
the same region within the control group. The uncoupling of FDG
uptake and walking speed is visualized for four regions in Figure 4.
Table 3 lists the all r-values and associated P-values.
DISCUSSION
Results from SPM analysis showed that patients with MS had
lower FDG uptake in ~40% of the brain compared to controls
as well as weaker associations with preferred walking speed. Inter-
estingly, the motor cortex, the origin of central motor command,
was not found to be associated to walking speed in patients with
MS (r =−0.496, P = 0.241). This data suggest that alterations in
task performance in patients with MS, such as walking, may be
due to network wide uncoupling of CNS activity.
LOWER FDG UPTAKE
Roelcke et al. (1997) previously showed a reduced central meta-
bolic rate of glucose in patients with MS. Possible explanations
are reduced brain volume and enlarged ventricles (Grassiot et al.,
2009), which are common effects of MS, and altered glucose
metabolism that has been shown in MS and other neurological
diseases (Mathur et al., 2014). One hypothesis that encompasses
both of these factors is that mitochondrial dysfunction can lead to
neurodegeneration (Su et al., 2009, 2013; Cambron et al., 2012).
Amorini et al. (2014) reported greatly elevated serum lactate levels
in patients with MS. They suggested this is due to mitochondrial
dysfunction, which results in a reduced oxidative capacity, and in
turn to a higher lactate concentration. Smith et al. (2003) inves-
tigated the effect of infused lactate on resting CNS FDG uptake
and found that FDG uptake was reduced with lactate infusion.
During exercise, it has also been shown that brain FDG uptake
can be reduced. This reduction was correlated with the increase in
lactate production (Kemppainen et al., 2005), although the inten-
sities at which this was found to happen were 30, 50, and 75%
V˙O2max. Even though these patients with MS were only mildly
disabled, a reduced brain volume and increased lactate utiliza-
tion could be driving the lower FDG uptake observed in this
study.
REDUCED ASSOCIATIONS BETWEEN BRAIN FDG UPTAKE AND
WALKING SPEED
Much of our knowledge of brain function has been obtained from
lesion studies. In these studies, focal lesions are created or patients
with naturally occurring lesions were studied. A hallmark of MS
is demyelinated lesions, which can be either active or dormant,
throughout the CNS (Kutzelnigg and Lassmann, 2014). Often
time’s clinical disability can be linked to the location and activ-
ity of these lesions (Rocca et al., 2002; Gil Moreno et al., 2013).
While no MRI measurements were performed for this study, it is
unlikely that any lesions the patients with MS had were all in the
same locations.
In the control group, we found moderate to strong correlations
with walking speed for most of the brain regions within the iden-
tified cluster. Many of these regions are involved in visual–spatial
processing, sensory/motor integration, and executive function. It
FIGURE 2 | Brain regions where patients with MS have lower FDG uptake after walking challenge. Walking speed has been modeled out as a nuisance
factor. Data are thresholded at P <0.01, FDR corrected.
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FIGURE 3 | SPM output of the areas of lower FDG uptake in patients with MS compared to controls. Within cluster information is displayed for the large
cluster (pFWE-corr <0.001, qFDR-corr <0.001, k e =93851) identified during analysis.
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Table 2 | SPM analysis of cluster-level differences between patients
with MS and healthy controls.
T Z puncorr MNI coordinates Region
5.28 3.79 0.000 12 36 −4 Cingulum_Ant_Ra
5.12 3.72 0.000 24 50 −4 Frontal_Sup_Orb_Ra
5.10 3.71 0.000 38 −6 −32 Fusiform_R
4.84 3.60 0.000 38 22 10 Frontal_Inf_Tri_R
4.80 3.58 0.000 38 42 40 Frontal_Mid_R
4.78 3.57 0.000 −28 20 −36 Temporal_Pole_Mid_L
4.77 3.57 0.000 36 −54 30 Angular_Ra
4.73 3.54 0.000 −24 14 −50 Fusiform_La
4.70 3.53 0.000 46 −30 −32 Cerebelum_6_Ra
4.62 3.49 0.000 34 14 4 Insula_R
4.62 3.49 0.000 6 64 −20 Frontal_Sup_Orb_R
4.60 3.48 0.000 42 −14 −12 Hippocampus_Ra
4.38 3.37 0.000 16 20 −8 Cuadate_R
4.36 3.36 0.000 −34 −22 −4 Hippocampus_La
4.35 3.36 0.000 68 0 6 Temporal_Sup_Ra
4.34 3.35 0.000 −30 −6 −20 Hippocampus_L
aVisually placed in nearest labeled area within the automatic anatomical labeling
(AAL) MRIcron template.
All locations represent areas of lower activity in the MS group vs. the CON group.
has been reported that the neural network for motor task perfor-
mance is highly integrative, and not limited to areas like the motor
cortex and supplemental motor areas, and can change depending
on the task being performed (Neely et al., 2013). These areas of cor-
tical activity have also been identified during walking and running
in other studies using near infrared spectroscopy (NIRS) (Suzuki
et al., 2004; Koenraadt et al., 2014) as well as during imagined walk-
ing with fMRI (Bakker et al., 2008). In patients with MS, however,
it appears that these network connections are altered, suggest-
ing a decoupling effect of brain activity and motor performance.
Only the insular cortex, calcarine sulcus, and hippocampus had
a significant association with walking speed in patients with MS.
The strength of these correlations was also very similar to those
within the healthy control group. Interestingly, the motor cortex
in the control group showed a strong correlation to walking speed
(r =−0.791,P = 0.019). The contributions of the motor cortex to
steady state walking is not completely understood, with conflict-
ing reports of its activity and importance being stated by multiple
sources (Bakker et al., 2008; La Fougere et al., 2010; Petersen et al.,
2012; Koenraadt et al., 2014). During gait challenges, it has also
been shown that areas like the supplemental motor areas and
prefrontal areas are more active to account for the continuous
alterations necessary to navigate the challenges (Suzuki et al., 2004;
Bakker et al., 2008; Koenraadt et al., 2014). With the increase in
disability and disease progression, it is possible that these areas
are used to a greater extend to maintain ambulation in patients
with MS and the inability to fully utilize them during walk may
contribute to the slower walking speed observed in these patients.
The calcarine sulcus is located within the primary visual cor-
tex, within the occipital lobe. Visual feedback is important for
most motor tasks (Zhang et al., 2011; Sarlegna and Mutha,
2014). It allows for the proper interpretation of the body in the
environment. Visual feedback also plays an important role in the
maintenance of balance (Prosperini et al., 2010), which is often
impaired in patients with MS. The insular cortex is a located medial
to the temporal lobe and is known as a motor/sensory association
area. The integration of sensory and motor cues are necessary for
the continuous updates of motor patterns (Smucny et al., 2013),
ensuring efficient task performance. The hippocampus connects to
the medial temporal lobe. This area has been implicated in motor
task performance through fMRI studies of recalled walking (La
Fougere et al., 2010; Wutte et al., 2012). It is believed that this area
stores the motor patterns that are recalled during walking. Recall
of these motor patterns would mostly occur through connec-
tions with the hippocampus as well as sensory/motor connections
throughout the cortex of the frontal, parietal, and temporal lobes.
POTENTIAL PHYSIOLOGICAL MECHANISMS FOR WALKING
IMPAIRMENTS IN PATIENTS WITH MS
Demyelinating lesions often occur throughout the CNS, with no
two individuals having lesions at the exact same loci. The decou-
pling of the CNS and motor task performance may partially
explain why many symptoms, such as difficulties walking, are
shared between so many patients with MS. To maintain mental
and physical function the brain forms new connections within
itself to compensate for damage. This plasticity may result in the
network wide alterations in glucose uptake, which we show is
uncoupled with motor task performance. It is unclear whether
these alterations in glucose uptake are causative of disability, or
compensatory to maintain function. Further research is necessary
to elucidate how alterations in CNS activity influence motor task
performance in patients with MS.
METHODOLOGICAL CONSIDERATIONS
One limitation of this investigation is the lack of MRI data. Com-
bining structural information like brain volume as well as lesion
locations could provide additional insight in to why certain areas
were correlated with walking speed while others were not. Brain
atrophy is very common in patients with MS. The normaliza-
tion of their PET image to a standard template could introduce
error, which increases with greater atrophy. As the amount of
atrophy is increased an SUV image would be stretched more to
fit the standard template. If varying amounts of atrophy within
the MS existed, it could in part explain the lack of correlation
between brain ROI and walking speed. The average disease dura-
tion of patients with MS in this study was 8.9 years, with a range
of 1–19 years, so varying amounts of atrophy can be expected.
However, the three ROIs that were found to be significantly corre-
lated with walking speed in the MS group, has similar r-values and
P-values as that of the control group. Since atrophy is common
in MS using individualized MR images for normalization may be
able to account for the variance due to atrophy and should be
performed in future studies. Another limitation is the lack of a
baseline FDG PET image so that relative activation/deactivation
could be estimated for the groups. Future studies utilizing both
MRI and PET may provide greater information on the associa-
tions between structure and function within the human brain.
Another aspect to consider is the importance of spinal cord acti-
vated motor commands from central pattern generators. It is
possible that an increased reliance on these motor neurons could
reduce correlations with walking performance and the brain.
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FIGURE 4 |Visual representation of correlations between walking speed
and brain region FDG uptake. In each case, the strength of the correlation is
less in patients with MS compared to controls. As well as correlations being
weaker, patients with MS show no statistical significance while correlations
for the control group all reach statistical significance. (A) Motor cortex,
(B) frontal cortex, (C) cerebellum, (D) anterior cingulate.
Table 3 | Pearsons’ correlations between walking speed and brain
region FDG uptake.
Brain region MS CON
r -value P -value r -value P -value
Frontal cortex −0.484 0.224 −0.813 0.014*
Occipital cortex −0.664 0.073 −0.786 0.021*
Lateral temporal cortex −0.664 0.073 −0.818 0.013*
Medial temporal cortex −0.636 0.090 −0.832 0.010*
Motor cortex −0.496 0.241 −0.791 0.019*
Cerebellum −0.424 0.295 −0.835 0.010*
Insula −0.740 0.036* −0.817 0.013*
Hippocampus −0.718 0.045* −0.751 0.032*
Anterior cingulum −0.414 0.308 −0.800 0.017*
Precuneus −0.603 0.113 −0.799 0.017*
Calcarine −0.767 0.026* −0.750 0.032*
Lingual −0.680 0.064 −0.850 0.007*
Fusiform −0.626 0.097 −0.851 0.007*
Thalamus −0.324 0.433 −0.680 0.063
Caudate −0.557 0.151 −0.704 0.051
*P<0.050.
CONCLUSION
Mildly disabled patients with MS have been shown to decrements
in function task performance. In this sample, these decrements
were reflected by a significantly slower self-selected walking speed.
These patients also demonstrated reduced FDG uptake into ~40%
of the brain. Only 3 out of 15 regions identified within the patients
with MS,compared to 13 out of 15 regions in healthy controls,were
found to be correlated with their walking speed. This may suggest
a decoupling of brain glucose utilization and motor task perfor-
mance. Whether this decoupling is a compensatory mechanism
to maintain function or contributes to the decrements in motor
task performance requires further studies. Future research studies
need to be conducted to identify how to preserve the associa-
tions between brain glucose uptake and motor task performance in
order to lessen the effects motor decrements have on the functional
abilities of patients with MS.
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